Therefore, ongoing studies are needed to define which patients with ALK-rearranged NSCLC in the era of brain-penetrable TKI therapy will continue to benefit from upfront radiotherapy due to being at higher risk for intracranial progression. Here, ALK is linked to non-small cell lung carcinoma.